zurück

Zanubrutinib (new indication: chronic lymphocytic leukemia (CLL), for relapsed and/or refractory patients)

 

Subject:

  • Active Substance: Zanubrutinib
  • Name: Brukinsa®
  • Therapeutic area: Chronic lymphocytic leukemia (CLL)
  • Pharmaceutical company: BeiGene Germany GmbH

 

Time table:

  • Start: 15.12.2022
  • Final decision by G-BA: 15.06.2023

 

Final decision:

  1. Patients who have not yet received a BTK inhibitor and/or BCL2 inhibitor: Indication for a minor additional benefit
  2. Patients after prior therapy with at least one BTK inhibitor: No additional benefit proved
  3. Patients after prior therapy with at least one BCL2 inhibitor: No additional benefit proved
  4. Patients after prior therapy with at least one BTK inhibitor and one BCL2 inhibitor: No additional benefit proved